MDL | MFCD00036902 |
---|---|
Molecular Weight | 467.58 |
Molecular Formula | C22H46NO7P |
SMILES | CCCCCCCCCCCCCC(OC[C@@H](O)COP(OCC[N+](C)(C)C)([O-])=O)=O |
LysoPC(14:0/0:0) is a lysophospholipid (LyP). It is a monoglycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. LysoPC(14:0/0:0) has potent antispasmodic effect [1] .
Human Endogenous Metabolite |
Of the saturated fatty acid-containing L-α-lysolecithins (LPC), palmitoyl-LPC shows the strongest antispasmodic effect against acetylcholine- or histamine-induced guinea pig ileum contraction; the order of potency of the others is (LysoPC(14:0/0:0)) myristoyl- > stearoyl-, lauroyl- > decanoyl-LPC. Incorporation of a cis-double bond into the C18 fatty acid chain of LPC resulted in a slight decrease of the antispasmodic effect [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Solid
Room temperature in continental US; may vary elsewhere.
Powder | -20°C | 3 years |
---|---|---|
4°C | 2 years | |
In solvent | -80°C | 6 months |
-20°C | 1 month |
Ethanol : 50 mg/mL ( 106.93 mM ; Need ultrasonic)
Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
---|
1 mM | 2.1387 mL | 10.6934 mL | 21.3867 mL |
5 mM | 0.4277 mL | 2.1387 mL | 4.2773 mL |
10 mM | 0.2139 mL | 1.0693 mL | 2.1387 mL |